Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malaria

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 67 articles:
HTML format



Single Articles


    June 2021
  1. DASSAH S, Adu B, Sirima SB, Mordmuller B, et al
    Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00760.
    PubMed     Abstract available


    April 2021
  2. VEKEMANS J, Schellenberg D, Benns S, O'Brien K, et al
    Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00409.
    PubMed     Abstract available


  3. DE SL, May S, Shah K, Slawinski M, et al
    Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00376.
    PubMed     Abstract available


    February 2021
  4. DAS SC, Price JD, Gosling K, MacLennan N, et al
    Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00158.
    PubMed     Abstract available


    January 2021
  5. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Cox C, et al
    Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31590.
    PubMed     Abstract available


  6. CHAUDHURY S, MacGill RS, Early AM, Bolton JS, et al
    Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31635.
    PubMed     Abstract available


    December 2020
  7. SUAU R, Vidal M, Aguilar R, Ruiz-Olalla G, et al
    RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31606.
    PubMed     Abstract available


    October 2020
  8. MO AXY, Pesce J, Augustine AD, Bodmer JL, et al
    Understanding vaccine-elicited protective immunity against pre-erythrocytic stage malaria in endemic regions.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31253.
    PubMed     Abstract available


  9. THOMPSON HA, Hogan AB, Walker PGT, White MT, et al
    Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31251.
    PubMed     Abstract available


  10. EZOE S, Palacpac NMQ, Tetsutani K, Yamamoto K, et al
    First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).
    Vaccine. 2020 Oct 1. pii: S0264-410X(20)31227.
    PubMed     Abstract available


    September 2020
  11. VAN DER GRAAF R, Macklin R, Rid A, Bhan A, et al
    Integrating public health programs and research after the malaria vaccine implementation program (MVIP): Recommendations for next steps.
    Vaccine. 2020 Sep 24. pii: S0264-410X(20)31132.
    PubMed     Abstract available


    June 2020
  12. SCARIA PV, Chen BB, Rowe CG, Alani N, et al
    Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.
    Vaccine. 2020 Jun 26. pii: S0264-410X(20)30790.
    PubMed     Abstract available


  13. OUATTARA A, Niangaly A, Adams M, Coulibaly D, et al
    Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30821.
    PubMed     Abstract available


  14. CHEUNG YB, Ma X, Lam KF, Milligan P, et al
    Estimation of the primary, secondary and composite effects of malaria vaccines using data on multiple clinical malaria episodes.
    Vaccine. 2020 Jun 11. pii: S0264-410X(20)30753.
    PubMed     Abstract available


    May 2020
  15. ONEKO M, Cherop YR, Sang T, Gutman JR, et al
    Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya.
    Vaccine. 2020 May 19. pii: S0264-410X(20)30614.
    PubMed     Abstract available


  16. NOUATIN O, Ateba Ngoa U, Ibanez J, Dejon-Agobe JC, et al
    Effect of immune regulatory pathways after immunization with GMZ2 malaria vaccine candidate in healthy lifelong malaria-exposed adults.
    Vaccine. 2020 May 5. pii: S0264-410X(20)30540.
    PubMed     Abstract available


    April 2020
  17. BELL GJ, Loop M, Topazian HM, Hudgens M, et al
    Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi.
    Vaccine. 2020 Apr 30. pii: S0264-410X(20)30511.
    PubMed     Abstract available


    March 2020
  18. TACHIBANA M, Baba M, Takashima E, Tsuboi T, et al
    The C-terminal region of the Plasmodium yoelii microgamete surface antigen PyMiGS induces potent anti-malarial transmission-blocking immunity in mice.
    Vaccine. 2020;38:3129-3136.
    PubMed     Abstract available


  19. ASANTE KP, Ansong D, Kaali S, Adjei S, et al
    Immunogenicity and safety of the RTS,S/AS01 malaria vaccine co-administered with measles, rubella and yellow fever vaccines in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.
    Vaccine. 2020 Mar 16. pii: S0264-410X(20)30358.
    PubMed     Abstract available


    February 2020
  20. QIU Y, Zhao Y, Liu F, Ye B, et al
    Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.
    Vaccine. 2020 Feb 21. pii: S0264-410X(20)30184.
    PubMed     Abstract available


  21. SSEMAGANDA A, Giddam AK, Low LM, Liu XQ, et al
    Mannosylated liposomes formulated with whole parasite P. falciparum blood-stage antigens are highly immunogenic in mice.
    Vaccine. 2020;38:1494-1504.
    PubMed     Abstract available


    November 2019
  22. OTIENO L, Guerra Mendoza Y, Adjei S, Agbenyega T, et al
    Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
    Vaccine. 2019 Nov 7. pii: S0264-410X(19)31466.
    PubMed     Abstract available


    June 2019
  23. VOM STEEG LG, Flores-Garcia Y, Zavala F, Klein SL, et al
    Irradiated sporozoite vaccination induces sex-specific immune responses and protection against malaria in mice.
    Vaccine. 2019 Jun 28. pii: S0264-410X(19)30852.
    PubMed     Abstract available


    May 2019
  24. CAWLFIELD A, Genito CJ, Beck Z, Bergmann-Leitner ES, et al
    Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
    Vaccine. 2019 May 28. pii: S0264-410X(19)30696.
    PubMed     Abstract available


    February 2019
  25. KINGSTON NJ, Kurtovic L, Walsh R, Joe C, et al
    Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
    Vaccine. 2019 Feb 14. pii: S0264-410X(19)30132.
    PubMed     Abstract available


    January 2019
  26. COELHO CH, Gazzinelli-Guimaraes PH, Howard J, Barnafo E, et al
    Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel(R) in mice.
    Vaccine. 2019 Jan 23. pii: S0264-410X(19)30090.
    PubMed     Abstract available


  27. RODRIGUES-DA-SILVA RN, Correa-Moreira D, Soares IF, de-Luca PM, et al
    Immunogenicity of synthetic peptide constructs based on PvMSP9E795-A808, a linear B-cell epitope of the P. vivax Merozoite Surface Protein-9.
    Vaccine. 2019;37:306-313.
    PubMed     Abstract available


  28. HEALY SA, Fried M, Richie T, Bok K, et al
    Malaria vaccine trials in pregnant women: An imperative without precedent.
    Vaccine. 2019 Jan 6. pii: S0264-410X(18)31698.
    PubMed     Abstract available


    October 2018
  29. KANOI BN, Nagaoka H, Morita M, White MT, et al
    Comprehensive analysis of antibody responses to Plasmodium falciparum erythrocyte membrane protein 1 domains.
    Vaccine. 2018;36:6826-6833.
    PubMed     Abstract available


    August 2018
  30. CHICHESTER JA, Green BJ, Jones RM, Shoji Y, et al
    Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Vaccine. 2018 Aug 17. pii: S0264-410X(18)31159.
    PubMed     Abstract available


    June 2018
  31. PANDEY RK, Ali M, Ojha R, Bhatt TK, et al
    Development of multi-epitope driven subunit vaccine in secretory and membrane protein of Plasmodium falciparum to convey protection against malaria infection.
    Vaccine. 2018 Jun 16. pii: S0264-410X(18)30748.
    PubMed     Abstract available


    April 2018
  32. AN SJ, Scaria PV, Chen B, Barnafo E, et al
    Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    Vaccine. 2018 Apr 19. pii: S0264-410X(18)30518.
    PubMed     Abstract available


  33. FONSECA JA, McCaffery JN, Caceres J, Kashentseva E, et al
    Inclusion of the murine IgGkappa signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.
    Vaccine. 2018 Apr 12. pii: S0264-410X(18)30474.
    PubMed     Abstract available


    March 2018
  34. NLINWE ON, Kusi KA, Adu B, Sedegah M, et al
    T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development.
    Vaccine. 2018 Mar 21. pii: S0264-410X(18)30368.
    PubMed     Abstract available


    February 2018
  35. SIMON N, Friedrich O, Kappes B
    Quantification of human complement factor H binding to asexual malaria blood stages by an enzyme-linked immunosorbent assay.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30153.
    PubMed     Abstract available


  36. NIELSEN CM, Vekemans J, Lievens M, Kester KE, et al
    RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype.
    Vaccine. 2018 Feb 10. pii: S0264-410X(18)30142.
    PubMed     Abstract available


    December 2017
  37. KABA SA, Karch CP, Seth L, Ferlez KMB, et al
    Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine.
    Vaccine. 2017 Dec 18. pii: S0264-410X(17)31728.
    PubMed     Abstract available


    November 2017
  38. ROESTENBERG M, Mordmuller B, Ockenhouse C, Mo A, et al
    The frontline of controlled human malaria infections: A report from the controlled human infection models Workshop in Leiden University Medical Centre 5 May 2016.
    Vaccine. 2017 Nov 16. pii: S0264-410X(17)31522.
    PubMed     Abstract available


    October 2017
  39. SHIRATSUCHI T, Rai U, Kaneko I, Zhang M, et al
    A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31474.
    PubMed     Abstract available


  40. PERRAUT R, Varela ML, Joos C, Diouf B, et al
    Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
    Vaccine. 2017 Oct 14. pii: S0264-410X(17)31391.
    PubMed     Abstract available


    September 2017
  41. SIRIMA SB, Durier C, Kara L, Houard S, et al
    Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Vaccine. 2017 Sep 22. pii: S0264-410X(17)31247.
    PubMed     Abstract available


  42. VENKATRAMAN N, Anagnostou N, Bliss C, Bowyer G, et al
    Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M.
    Vaccine. 2017 Sep 20. pii: S0264-410X(17)31248.
    PubMed     Abstract available


    June 2017
  43. GENITO CJ, Beck Z, Phares TW, Kalle F, et al
    Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Vaccine. 2017 Jun 5. pii: S0264-410X(17)30729.
    PubMed     Abstract available


    May 2017
  44. SINGH SK, Thrane S, Janitzek CM, Nielsen MA, et al
    Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Vaccine. 2017 May 31. pii: S0264-410X(17)30690.
    PubMed     Abstract available


  45. ZHU D, Wu Y, McClellan H, Dai W, et al
    Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel(R).
    Vaccine. 2017;35:3232-3238.
    PubMed     Abstract available


  46. GBEDANDE K, Fievet N, Viwami F, Ezinmegnon S, et al
    Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae.
    Vaccine. 2017 May 17. pii: S0264-410X(17)30635.
    PubMed     Abstract available


  47. FONSECA JA, McCaffery JN, Kashentseva E, Singh B, et al
    A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30554.
    PubMed     Abstract available


  48. LI X, Huang J, Kawamura A, Funakoshi R, et al
    Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30578.
    PubMed     Abstract available


    April 2017
  49. CHATTOPADHYAY R, Pratt D
    Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective.
    Vaccine. 2017 Apr 18. pii: S0264-410X(17)30406.
    PubMed    



  50. Malaria vaccine: WHO position paper, January 2016 - Recommendations.
    Vaccine. 2017 Apr 3. pii: S0264-410X(16)30982.
    PubMed     Abstract available


    March 2017
  51. LUO K, Zavala F, Gordy J, Zhang H, et al
    Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
    Vaccine. 2017 Mar 22. pii: S0264-410X(17)30369.
    PubMed     Abstract available


  52. FORD T, Wenden C, Mbekeani A, Dally L, et al
    Cryopreservation-related loss of antigen-specific IFNgamma producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.
    Vaccine. 2017 Mar 9. pii: S0264-410X(17)30241.
    PubMed     Abstract available


  53. SETH L, Bingham Ferlez KM, Kaba SA, Musser DM, et al
    Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.
    Vaccine. 2017 Mar 5. pii: S0264-410X(17)30243.
    PubMed     Abstract available


    January 2017
  54. ANDERSSON AC, Resende M, Salanti A, Nielsen MA, et al
    Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.
    Vaccine. 2017 Jan 25. pii: S0264-410X(17)30033.
    PubMed     Abstract available


  55. KANOI BN, Takashima E, Morita M, White MT, et al
    Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
    Vaccine. 2017 Jan 12. pii: S0264-410X(17)30003.
    PubMed     Abstract available


  56. MILLIGAN P, Flach C, Theisen M
    Efficacy of the GMZ2 malaria vaccine in African children.
    Vaccine. 2017;35:202.
    PubMed    


  57. EJIGU DA
    When should a time at risk start in efficacy malaria vaccine trials?
    Vaccine. 2017;35:201.
    PubMed    


  58. GESSNER BD, Knobel DL, Conan A, Finn A, et al
    Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine?
    Vaccine. 2017 Jan 5. pii: S0264-410X(17)30001.
    PubMed     Abstract available


    December 2016
  59. MATTHIESSEN L, Lang H, Klimathianaki M, Hanrahan F, et al
    European strategy for vaccine development against infectious diseases.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)30952.
    PubMed     Abstract available


  60. PEHRSON C, Heno KK, Adams Y, Resende M, et al
    Comparison of functional assays used in the clinical development of a placental malaria vaccine.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31235.
    PubMed     Abstract available


    November 2016
  61. DATTA D, Bansal GP, Gerloff DL, Ellefsen B, et al
    Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Vaccine. 2016 Nov 29. pii: S0264-410X(16)31143.
    PubMed     Abstract available


  62. GALACTIONOVA K, Tediosi F, Camponovo F, Smith TA, et al
    Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
    Vaccine. 2016 Nov 24. pii: S0264-410X(16)31103.
    PubMed     Abstract available


    October 2016
  63. BRICKLEY EB, Coulibaly M, Gabriel EE, Healy SA, et al
    Utilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: A systematic review of methods and case study.
    Vaccine. 2016 Oct 24. pii: S0264-410X(16)30945.
    PubMed     Abstract available


    September 2016
  64. SPEARMAN P, Mulligan M, Anderson EJ, Shane AL, et al
    A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
    Vaccine. 2016 Sep 30. pii: S0264-410X(16)30855.
    PubMed     Abstract available


  65. NTEGE EH, Arisue N, Ito D, Hasegawa T, et al
    Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Vaccine. 2016 Sep 28. pii: S0264-410X(16)30841.
    PubMed     Abstract available


    May 2016
  66. BLAGBOROUGH AM, Musiychuk K, Bi H, Jones RM, et al
    Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Vaccine. 2016 May 10. pii: S0264-410X(16)30290.
    PubMed     Abstract available


    March 2016
  67. BALDWIN SL, Roeffen W, Singh SK, Tiendrebeogo RW, et al
    Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
    Vaccine. 2016 Mar 16. pii: S0264-410X(16)00327.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malaria is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: